Skip to main content

Advertisement

SpringerLink
Log in

Update in HIV Medicine for the Generalist

  • Update
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Siegfried N, Muller M, Deeks J, et al. HIV and male circumcision–a systematic review with assessment of the quality of studies. Lancet Infect Dis. 2005;5(3):165–73. Mar.

    PubMed  CAS  Google Scholar 

  2. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 trial. PLoS Med. 2005;211:e298. Nov.

    Article  PubMed  Google Scholar 

  3. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet. 2007;369:643–56.

    Article  PubMed  Google Scholar 

  4. Wawer M, Kigozi G, Serwadda D, et al. Trial of male circumcision in HIV+ men, Rakai, Uganda: Effects in HIV+ men and in women partners. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA. February 3–6, 2008. Abstract 33LB.

  5. Joint United Nations Programme on HIV/AIDS, World Health Organization. New Data on Male Circumcision and HIV Prevention: Policy and Programme Implications. 2007. Available at: http://data.unaids.org/pub/Report/2007/mc_recommendations_en.pdf. Accessed September 29, 2008.

  6. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR. Centers for Disease Control. 2006;55RR-141–17.

    Google Scholar 

  7. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med. 2005;352:586–95.

    Article  PubMed  CAS  Google Scholar 

  8. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570–85.

    Article  PubMed  CAS  Google Scholar 

  9. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2006 October 10, 2006. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL000629.pdf. Accessed September 29, 2008.

  10. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2007 December 1, 2007. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL000721.pdf. Accessed September 29, 2008.

  11. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251–60. Jan 19.

    Article  PubMed  CAS  Google Scholar 

  12. Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: Week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA. February 3–6, 2008. Abstract 790.

  13. Johnson M, Campbell T, Clotet B, et al. DUET-2: Week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA. February 3–6, 2008. Abstract 791.

  14. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the randomized evaluation of strategic intervention in multi-drug resistant patients with tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466–75.

    Article  PubMed  CAS  Google Scholar 

  15. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22:1389–97.

    Article  PubMed  CAS  Google Scholar 

  16. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169–78.

    Article  PubMed  CAS  Google Scholar 

  17. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomised controlled phase III trial. Lancet. 2007;370:49–58.

    Article  PubMed  CAS  Google Scholar 

  18. Hardy D, Reynes J, Kornourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA. February 3–6, 2008. Abstract 792.

  19. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine/lamivudine), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: Week 48 results of the MERIT study. Presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia. July 22–25, 2007. Abstract WESS104.

  20. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125–33.

    Article  PubMed  CAS  Google Scholar 

  21. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–54.

    Article  PubMed  Google Scholar 

  22. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;10:1603–14.

    Article  Google Scholar 

  23. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121–2.

    Article  PubMed  CAS  Google Scholar 

  24. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–32.

    Article  PubMed  CAS  Google Scholar 

  25. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46:1111–8.

    Article  PubMed  CAS  Google Scholar 

  26. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed September 29, 2008.

  27. Lundgren JD. Combination antiretroviral therapy and the risk of myocardial infarction: The data collection on adverse events of anti-HIV drugs (DAD) study group. N Engl J Med. 2003;349:1993–2003.

    Article  PubMed  Google Scholar 

  28. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356–62.

    PubMed  CAS  Google Scholar 

  29. Panel on Antiretroviral Guidelines for Adults and Adolescents. DHHS adults and adolescents antiretroviral treatment guidelines Panel’s communication regarding abacavir. Available at: http://aidsinfo.nih.gov/contentfiles/ABCComm.pdf. Accessed September 29, 2008.

Download references

Acknowlegements

Dr. Gifford is supported in part by grants from the Department of Veteran Affairs QUERI-HIV/Hepatitis Program (no. HIV 98–000), the VA HSR&D Center of Excellence, Bedford (no. HFP 90–011), and the NIMH HIV Secondary Prevention and Translation Branch, (no. 1 R01 MH076911–01A2). Dr. Sullivan is a Robert Wood Johnson Physician Faculty Scholar and is supported, in part, by the Health Resources Services Administration (1H97HA03800).

The authors would like to thank Dr. Joel Gallant for assisting with selection of medication trials to include in this update and for his review and comments on the Table 1.

This update was presented at the meeting of the Society of General Internal Medicine in April 2008.

Conflict of Interest

None disclosed.

Author information

Authors and Affiliations

  1. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Amina A. Chaudhry MD MPH, Joseph Cofrancesco Jr. MD MPH & Gail Berkenblit MD, PhD

  2. Department of Medicine, VA New England Healthcare and Boston University School of Medicine, Boston, MA, USA

    Allen L. Gifford MD

  3. Department of Medicine, University of Wisconsin School of Medicine, Madison, WI, USA

    James Sosman MD

  4. Department of Medicine, Yale University School of Medicine, New Haven, CT, USA

    Lynn E. Sullivan MD

Authors
  1. Amina A. Chaudhry MD MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Allen L. Gifford MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph Cofrancesco Jr. MD MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James Sosman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gail Berkenblit MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lynn E. Sullivan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amina A. Chaudhry MD MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chaudhry, A.A., Gifford, A.L., Cofrancesco Jr., J. et al. Update in HIV Medicine for the Generalist. J GEN INTERN MED 24, 276–282 (2009). https://doi.org/10.1007/s11606-008-0851-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11606-008-0851-2

Keywords

Search

Navigation